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ABSTRACT
Objective: The aims of this research are to evaluate the effect of rituximab on wound healing, some hematological parameters, histological changes in 
wound healing, and histopathological changes in some organs in male mice.
Methods: Totally, 15 adult male mice (25-30 g) were enrolled in this study. Animals were kept in the animal house College of Medicine/University 
of Babylon, and the temperature was controlled on 25°C and 14 hrs light and 10 hrs dark cycles. The animals were provided with standard diet and 
water ad libitum. The animals were divided randomly into 3 groups, five mice in each group, Group 1 (control group) received no treatment, Group 2 
received rituximab 1 m/kg, IP, at days 0, 5, and 10 after wounding, in Group 3, rituximab was topically applied to the wound at days 0, 5, and 10 after 
wounding.
Results: The results yield that the wound healing significantly decreased (p<0.05) in Groups 2 and 3 as compared to control group. While the results 
regarding white blood cells (WBCs) count, there is a significant decrease in WBC count in Group 2 (p>0.05). Platelets and red blood cell count in 
significantly increased in Group 3 as compared to control group (p<0.05). There were no histopathological changes in the skin, kidneys, and spleen. 
In liver, nonsignificant histopathological changes (p>0.05) found in Group 2 and 3 as compared to control group.
Conclusion: Rituximab delays wound healing and reduces WBC count in male mice.
Keywords: Rituximab, Wound healing, Lymphocyte, CD20, White blood cells, Mice.
INTRODUCTION
The healing of the wound is a vital process by which the body tissue repairs 
itself after trauma, in undamaged skin, the epidermis (surface layer) 
and dermis (deeper layer) form a protective physical barrier against 
the external environment [1]. This process is divided into many phases: 
Blood clotting (hemostasis) phase, inflammation phase, tissue growth 
phase (proliferation), and tissue remodeling phase (maturation), blood 
clotting may be considered to be part of the inflammation stage instead 
of a separate stage [2]. Hemostasis (blood clotting): Within the first 
few minutes after injury, platelets in the blood begin to aggregate at the 
injured site [3]. Inflammation: During this phase, dead and damaged 
cells are cleared out, along with bacteria and other pathogens or debris. 
This takes place through the process of phagocytosis, where white 
blood cells (WBCs) “engulf” debris. Platelet-derived growth factors 
are released into the wound that causes the migration and division of 
cells during the proliferative phase [4]. Proliferation (growth of new 
tissue): In this phase, angiogenesis, collagen deposition, granulation 
tissue formation, epithelialization, and wound contraction occur [5]. 
Maturation (remodeling): During maturation and remodeling, collagen 
is realigned along tension lines, and cells that are no longer needed are 
removed by programmed cell death, or apoptosis [6]. The effects of anti-
inflammatory and immunomodulatory medications on the different 
stages of the wound healing process can be widespread, and the initial 
inflammatory may be blunted, or the proliferative and remodeling 
phases may be abnormal or prolonged [7].
Rituximab is a drug that is licensed for the treatment of relapsed or 
refractory B-cell lymphoma [8,9] and autoimmune diseases such as 
rheumatoid arthritis [10]. It lyses B lymphocytes by binding to CD20 
antigen found on the surface all B-lymphocyte tumors and activating 
complement. It is also used with other chemotherapeutic agents to 
sensitizes resistant cells [11]. It is effective in 40-50% of B-cell lymphomas 
when combined with standard chemotherapy [8]. Serum half-life is 59.8 
hrs after 1st dose and 17.4 hrs after 4th infusion [11]. Rituximab can be 
detected in the serum for many months after the dose of the drug [12]. 
There are different mechanisms to lyses B-cells by rituximab including 
antibody-dependent cellular cytotoxicity [8], complement dependent 
cytotoxicity [8,9], and stimulation of apoptotic pathway [2,9]. In all cases 
in which rituximab was given, a rapid decreasing of circulating B-cells 
occurred [13]. B-cell recovery started at 6-9 months after completion 
of treatment [2]. Side effects of rituximab include fevers (43%), chills, 
nausea, vomiting, orthostatic hypotension (10%), and bronchospasm 
(8%). Neutropenia and thrombocytopenia may occur [11].
Aims of the study
The aims of this study were to evaluate the effects of rituximab on the 
wound healing and the effects on different organs such as liver, spleen, 
and kidneys in the mice.
METHODS
Animals
Totally, 15 adult male mice (25-30 g) were enrolled in this study. 
Animals were kept in the animal house of College of Medicine/Babylon 
University, and the temperature was controlled on 25°C and 14 hrs light 
and 10 hrs dark cycles. The animals were provided with standard diet 
and water ad libitum.
Incision wound model
Each mouse was anesthetized by ether. The dorsal skin was shaved then 
cleaned with 70% alcohol. A linear dorsal incision (1 cm) was made 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.15458
Research Article
113
Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 112-116
 Selman et al. 
Fig. 1: A comparison of the mean differences of the lengths of the 
wounds in different groups at different days (Group 1 [control 
group] received no treatment. Group 2 received rituximab 1 m/kg, 
IP, at days 0, 5, and 10 after wounding. In Group 3, rituximab was 
topically applied to the wound at days 0, 5, and 10 after wounding)
Fig. 2: A comparison of the mean differences of the number of 
white blood cell between different groups (Group 1 [control 
group] received no treatment. Group 2 received rituximab 1 m/kg, 
IP, at days 0, 5, and 10 after wounding. In Group 3, rituximab was 
topically applied to the wound at days 0, 5, and 10 after wounding)
through the skin. The wound was left uncovered, and the mice housed 
in individual cages postoperatively. The animals were divided groups, 
five mice in each randomly into 3 group. Group 1 (control group) 
received no treatment. Group 2 received rituximab 1 m/kg, IP, at days 0, 
5, and 10 after wounding. In Group 3, rituximab was topically applied to 
the wound at days 0, 5, and 10 after wounding.
Blood and histopathological study
At 15th day, blood samples were taken by direct heart puncture, and the 
healing tissues were processed for histological study. Liver, spleen, and 
kidneys were dissected for histopathological study.
Tissues samples preparations
Liver, spleen, and kidneys were histologically prepared for paraffin 
section according to Bancroft and Stevens (1987) as follows: Fixation, 
dehydration, clearing, impregnation, embedding, sectioning, and 
dewaxing and hydration.
Statistical analysis
The data are expressed as the mean±standard error of mean. The 
difference among means has been analyzed by one-way ANOVA. The 
value of p<0.05 was considered as statistically significant.
RESULTS
Effects of rituximab on the wound healing
The lengths of the wound significantly decreased (p<0.05) in the control 
group as compared to Groups 2 and 3 (Tables 1 and 2, Fig. 1, Picture 1). 
The wound healing, also, significantly decreased (p<0.05) in Group 2 as 
compared to Group 3 (Table 3 and Fig. 1).
Hematological effects of rituximab
WBCs significantly significantly decreased (p<0.05) in Group 2 as 
compared with control group, whereas there were no significant 
differences (p>0.05) between control group and Group 3 (Table 4 and 
Fig. 2). Red blood cells (RBCs) significantly significantly increased 
(p<0.05) in Group 3 as compared with control group, whereas there 
were no significant differences (p>0.05) between control group and 
Group 2 (Table 5 and Fig. 3). Platelets significantly increased (p<0.05) 
Table 1: The means±SEM of the wound length of control 
Group 1 (control group) and Group 2 (received rituximab 
1 m/kg, IP, at days 0, 5, and 10 after wounding)
Duration Means±SEM of 
wound length (mm) 
of Group 1
Means±SEM of 
wound length (mm) 
of Group 2
p-value
2 days 6.8±1.30384 7.4±0.89443 >0.05
4 days 4.0±0.44721 5.6±0.50990 <0.05
6 days 0.8±0.83666 4.6±0.67823 <0.05
8 days 0.0±0.0 3.4±0.81240 <0.05
10 days 0.0±0.0 1.2±0.37417 <0.05
12 days 0.0±0.0 0.0±0.0 >0.05
SEM: Standard error of mean
Table 2: The means±SEM of the wound length of control 
Group 1 (control group) and Group 3 (rituximab was topically 
applied to the wound at days 0, 5, and 10 after wounding)
Duration Means±SEM of 
wound length (mm) 
of Group 1
Means±SEM of 
wound length (mm) 
of Group 3
p value
2 days 6.8±1.30384 6.6±0.4 >0.05
4 days 4.0±0.44721 5±0.31623 >0.05
6 days 0.8±0.83666 3±0.31623 <0.05
8 days 0.0±0.0 1.8±0.37417 <0.05
10 days 0.0±0.0 0.6±0.4 >0.05
12 days 0.0±0.0 0.0±0.0 >0.05
SEM: Standard error of mean
Picture 1: Pictures of wounds in different groups at different 
days (Group 1 [control group] received no treatment. Group 2 
received rituximab 1 m/kg, IP, at days 0, 5, and 10 after wounding. 
In Group 3, rituximab was topically applied to the wound at days 
0, 5, and 10 after wounding)
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in Group 3 as compared with control group, whereas there were no 
significant differences (p>0.05) between control group and Group 2 
(Table 6 and Fig. 4). There were no significant differences (p>0.05) 
in the platelet distribution width (PDW) between control group and 
Groups 2 and 3 (Table 7 and Fig. 5).
Tissue biopsy
Tissue biopsy from the skin, spleen, kidney, and liver had been 
underwent for all of the control, intraperitoneally and topically applied 
rituximab cases and had been studied histopathologically. No changes 
had been identified in the skin, kidney, spleen and pancreas apart from 
mild vascular congestion. Histopathological study showed hepatic 
spotty lytic necrosis of various grades, “focal necroinflammation,” 
recognizable as a small cluster of mononuclear cells (lymphocytes) 
with or without an adjacent identifiable apoptotic body or bodies 
(grades fluctuated between 1 and 4) and the highest grades were in 
the topically applied rituximab cases. However, these histopathological 
changes in the intraperitoneally and topically applied rituximab cases 
were being statistically insignificant when analyzed with the control 
group (Table 8, Fig. 6).
DISCUSSION
Rituximab is a drug designed as monoclonal, chimeric antibody that 
targets the CD20 antigen on B-cell, which expressed on normal and 
Table 3: The means±SEM of the wound length of control 
Group 2 (received rituximab 1 m/kg, IP, at days 0, 5, and 10 after 
wounding) and Group 3 (rituximab was topically applied to the 
wound at days 0, 5, and 10 after wounding)
Duration Means±SEM of 
wound length (mm) 
of Group 2
Means±SEM of 
wound length (mm) 
of Group 3
p value
2 days 7.4±0.89443 6.6±0.4 >0.05
4 days 5.6±0.50990 5±0.31623 >0.05
6 days 4.6±0.67823 3±0.31623 <0.05
8 days 3.4±0.81240 1.8±0.37417 <0.05
10 days 1.2±0.37417 0.6±0.4 >0.05
12 days 0.0±0.0 0.0±0.0 >0.05
SEM: Standard error of mean
Table 4: A comparison of the mean differences of the number 
of WBC between different groups (Group 1 [control group] 
received no treatment. Group 2 received rituximab 1 m/kg, 
IP, at days 0, 5, and 10 after wounding. In Group 3, rituximab 
was topically applied to the wound at days 0, 5, and 10 after 
wounding)
Duration Group 1 Group 2 Group 3
Group 1 X 2.24* 0.02
Group 2 −2.24* X −2.22*
Group 3 −0.02 2.22* X
*The mean difference is significant (p<0.05). WBC: White blood cell
Table 5: A comparison of the mean differences of the number of 
RBC between different groups (Group 1 [control group] received 
no treatment. Group 2 received rituximab 1 m/kg, IP, at days 0, 
5, and 10 after wounding. In Group 3, rituximab was topically 
applied to the wound at days 0, 5, and 10 after wounding)
Group 1 Group 2 Group 3
Group 1 X −0.98 −1.64*
Group 2 0.98 X −0.66
Group 3 1.64* −0.98 X
*The mean difference is statistically significant (p<0.05)
Table 6: A comparison of the mean differences of the number 
of platelets between different groups (Group 1 [control group] 
received no treatment. Group 2 received rituximab 1 m/kg, 
IP, at days 0, 5, and 10 after wounding. In Group 3, rituximab 
was topically applied to the wound at days 0, 5, and 10 after 
wounding)
Group 1 Group 2 Group 3
Group 1 X −166.6 −496*
Group 2 166.6 X −329
Group 3 496* 329.4 X
*The mean difference is statistically significant (p<0.05)
Table 8: Liver histopathological changes in the all 
groups (Group 1 [control group] received no treatment. 
Group 2 received rituximab 1 m/kg, IP, at days 0, 5, and 10 after 
wounding. In Group 3, rituximab was topically applied to the 
wound at days 0, 5, and 10 after wounding)











1 3 0 2 0 0 5
2 2 0 3 0 0 5
3 2 0 1 1 1 5
Total 
number
7 0 1 1 1 15
p=0.67
neoplastic B-cells, in addition, it playing a vital role in the treatment 
of newly diagnosed, and refractory indolent and aggressive CD20 
lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukemia, 
rituximab has recently used to treat autoimmune diseases such as 
systemic lupus erythematosus and rheumatoid arthritis [14].
Some studies reported that rituximab is useful in refractory immune 
thrombocytopenic purpura giving a good response rate, with 
complete remission and partial remission rate ranging from 48% to 
54% [15,16]. In our research, we have opportunity to test the effect 
of rituximab in wound healing as a model in animals laboratory as a 
new approach in rituximab treatment, when we compare the effect 
of rituximab on total number of WBCs, between the control group 
(Group 1) and group received rituximab intraperitoneal (Group 2) 
and group received rituximab locally (Group 3). The result showing 
that there is a significant difference decreasing in total number of 
WBCs between Group 1 and Group 2 as a result a targeting the CD20 
on lymphocytes following rituximab administration, and this result 
in agreement with other international studies [17]. While comparing 
between Group 1 and Group 3 in regarding the effect of rituximab on 
the RBCs count and platelets count, we notice there is a significant 
difference increasing for both RBCs count, and platelets count. This 
Table 7: A comparison of the mean differences of the number 
of PDW between different groups (Group 1 [control group] 
received no treatment. Group 2 received rituximab 1 m/kg, 
IP, at days 0, 5, and 10 after wounding. In Group 3, rituximab 
was topically applied to the wound at days 0, 5, and 10 after 
wounding)
Group 1 Group 2 Group 3
Group 1 X −0.24 −1.16
Group 2 0.24 X −0.92
Group 3 1.16 0.92 X
*The mean differences is statically significant (P<0.05).
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